Shells could stop snoring condition 8million suffer from in UK
Shankh blowing involves breathing in deeply before exhaling forcefully into a conch, the spiral-shaped shell from a species of sea snail. The small trial, led by researchers in India, involved 30 people aged with 19 and 65 with OSA.
OSA happens with the walls of the throat relax and narrow or close, with symptoms including choking noises, loud snoring and waking up a lot. The condition is thought to impact about eight million people in the UK.
READ MORE: Drivers urged to fill up tanks with Petrol and Diesel before Monday
READ MORE: Will strikes disrupt Ryanair flights to Alicante, Ibiza, Mallorca and Tenerife?
For the trial, 16 people were provided with a traditional shankh used in yogic practices and trained in how to use it properly before taking it home, while the remaining 14 people were asked to carry out deep breathing exercises. Both groups were encouraged to practice for a minimum of 15 minutes five days a week.
They were monitored during sleep and asked questions about sleep quality and how tired they felt during the day. After six months, the study found those who practised shankh blowing reported sleeping better and were 34% less sleepy during the day.
They also had higher levels of oxygen in the blood during the night and had four to five fewer apnoeas, where breathing stops during sleep, per hour on average. They also had higher levels of oxygen in their blood during the night.
Dr Krishna K Sharma, of the Eternal Heart Care Centre and Research Institute in Jaipur, India, said: 'The way the shankh is blown is quite distinctive. It involves a deep inhalation followed by a forceful, sustained exhalation through tightly pursed lips.
'This action creates strong vibrations and airflow resistance, which likely strengthens the muscles of the upper airway, including the throat and soft palate, areas that often collapse during sleep in people with OSA.
'The shankh's unique spiralling structure may also contribute to specific acoustic and mechanical effects that further stimulate and tone these muscles.'
Continuous positive airway pressure (Cpap) machines are the first line of treatment for OSA. They involve patients wearing a mask that blows pressurised air into the nose and throat while they sleep. However, they can be uncomfortable.
Speaking of Cpap, Dr Sharma said: 'While effective, many patients find it uncomfortable and struggle to use it consistently.'
He suggests shankh blowing could be a 'promising alternative'. 'Shankh blowing is a simple low-cost, breathing technique that could help improve sleep and reduce symptoms without the need for machines or medication,' Dr Sharma said.
Researchers are now planning a larger trial involving several hospitals. Dr Sharma added: 'This next phase will allow us to validate and expand on our findings in a broader, more diverse population and assess how shankh blowing performs over longer periods.
'We also want to study how this practice affects airway muscle tone, oxygen levels and sleep in greater detail. 'We're particularly interested in comparing shankh blowing with standard treatments like Cpap, and in examining its potential help in more severe forms of OSA.'
Reacting to the findings, Professor Sophia Schiza, head of the ERS group on sleep disordered breathing, based at the University of Crete, Greece, said: 'We know that OSA patients have poor quality of sleep, and higher risks of high blood pressure, strokes and heart disease.
'A proportion of patients experience sleepiness during the day. While Cpap and other treatments are available based on careful diagnosis of disease severity, there is still need for new treatments.
'This is an intriguing study that shows the ancient practice of shankh blowing could potentially offer an OSA treatment for selected patients by targeting muscles training.
'A larger study will help provide more evidence for this intervention which could be of benefit as a treatment option or in combination with other treatments in selected OSA patients.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Take-at-home drug can ‘disarm' cancer
A take-at-home tablet could boost the way cancer patients respond to chemotherapy, according to the medical experts who developed it. The drug, known as KCL-HO-1i, works by disarming a defence mechanism that tumours use to protect themselves. Early tests on mice found the drug even helped chemotherapy-resistant tumours to respond to treatment. It is hoped KCL-HO-1i can be trialled on humans, with researchers suggesting it could one day be a 'valuable companion drug' to chemotherapy, helping patients to avoid more aggressive treatments. Chemotherapy is used to treat many kinds of cancer and works by disrupting the way cancer cells grow and divide. However, it is not as effective as it should be in some patients because the body's own immune cells can act as a barrier around tumours. These cells produce a protein called heme oxygenase-1 (HO-1), which helps shield the tumour from the immune system and block the effects of chemotherapy. Exciting step forward KCL-HO-1i, created at King's College London (KCL), targets this protein to make tumours more responsive to treatment. Prof James Arnold, the head of the tumour immunology group at the university, said it discovered the cells responsible for protecting the body's immune system 'play a key role in blocking chemotherapy'. |He said: 'By targeting the enzyme they produce using KCL-HO-1i, we were able to help beneficial immune cells and chemotherapy drugs become significantly more effective. 'In laboratory models, even chemotherapy-resistant tumours became responsive to treatment, which is a really exciting step forward.' The drug has been designed for patients to take at home as a tablet between chemotherapy sessions. Spin-out company Early tests on mice, with the results published in the journal Science Translational Medicine, found the drug made breast cancer tumours more responsive to different types of chemotherapy. Researchers are now hopeful that trials involving patients with breast cancer and other forms of the disease could begin within two years. Prof James Spicer, a professor of experimental cancer medicine at KCL, said: 'Chemotherapy remains a key part of treatment for many patients with cancer, but too often it is not as effective or long-lasting as we might like. 'This research has identified a key reason for these limitations, and discovered a drug that we are keen to test in the clinic alongside established chemotherapy drugs.' Miraz Rahman, a professor of medicinal chemistry at KCL, added: 'If human trials are successful, KCL-HO-1i could become a valuable companion drug to existing cancer therapies – helping more patients to benefit from the treatments that are already available and reduce the need for more aggressive cancer therapies in the future.' The King's College London scientists have launched a spin-out company called Aethox Therapeutics. Tanya Hollands, the research information manager at Cancer Research UK, which supported the study alongside funding from the Medical Research Council, said: 'Researchers are increasingly learning how to make better use of existing cancer treatments, whether it's using them differently or in combination with new medicines, like this work suggests. 'Using combination therapies can help bring improved treatment options to patients more quickly, safely and affordably, because some components of the treatment have already been tested and used in the clinic. 'While early stage, it's exciting to see this potential new way to disarm cancer's ability to avoid detection by the immune system with a new drug, while also boosting the effectiveness of chemotherapy, and we look forward to seeing how this work progresses.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more. Solve the daily Crossword
Medscape
2 hours ago
- Medscape
Don't Reclassify Grade Group 1 Prostate Cancer: New Data
TOPLINE: Among US men with grade group 1 (GG1) prostate cancer, about 1 in 6 had intermediate- or high-risk disease, along with increased rates of adverse pathology and cancer-specific mortality. This finding suggests that GG1 prostate cancer should not be reclassified as noncancerous, as some experts have proposed. METHODOLOGY: Some experts have pushed to reclassify GG1 prostate cancer as a noncancerous entity to help reduce overtreatment. GG1 status is primarily designated via biopsy, but current guidelines recommend treatment decisions be based on a range of parameters, including prostate-specific antigen (PSA) levels, clinical stage, and tumor volume. Arguing against reclassification, researchers analyzed how localized GG1 prostate cancer varies by National Comprehensive Cancer Network (NCCN) risk groups, treatment, and cancer-specific outcomes. The researchers used the Surveillance, Epidemiology, and End Results database to identify 117,162 men diagnosed with localized GG1 prostate cancer (median age, 64 years) between January 2010 and December 2020. Patients were stratified by NCCN risk groups: low-risk, favorable intermediate-risk (n = 10,440; 9%), unfavorable intermediate-risk (n = 3145; 3%), and high-risk (n = 4539; 4%) — meaning 16% had non-low-risk disease. Outcomes included adverse pathology (> pT3, GG3-5 or pN+) at radical prostatectomy, prostate cancer-specific mortality, and trends in the management of GG1 prostate cancer. Comparisons with SEER patients with GG2 disease were included for context. The median follow-up was 58 months. TAKEAWAY: Rates of adverse pathology at prostatectomy increased from 16% in low-risk GG1 disease to 60% in high-risk GG1 disease. In adjusted analyses, compared with low-risk prostate cancer, favorable intermediate-risk GG1 prostate cancer was associated with 1.42-fold higher odds of adverse pathology, unfavorable intermediate-risk GG1 with 2.31-fold higher odds, and high-risk GG1 with 7.15-fold higher odds. At 10 years, the cumulative incidence of prostate cancer-specific mortality was 1.3% for low-risk GG1, 2.0% for favorable intermediate-risk GG1, 2.4% for unfavorable intermediate-risk GG1, and 4.7% for high-risk GG1. Compared with low-risk GG1 disease, the risk for death from prostate cancer was higher for favorable intermediate-risk (adjusted hazard ratio [aHR], 1.60), unfavorable intermediate-risk (aHR, 2.10), and high-risk (aHR, 3.58) GG1 prostate cancer. Mortality rates among patients with intermediate-risk GG1 cancer were comparable to that of patients with favorable intermediate-risk GG2 disease, at 2.1%. However, mortality among high-risk GG1 patients (4.7%) was significantly higher (P < .001). Regarding trends in the management of GG1 prostate cancer, active surveillance rose from 4% to 19% for unfavorable intermediate-risk disease, and from 9% to 25% for high-risk disease (P < .001). The data suggest high-risk patients are being undertreated, the authors wrote, 'possibly due to conflation of grade and risk.' IN PRACTICE: Prostate cancer-specific mortality for men with GG1 disease 'increases substantially across National Comprehensive Cancer Network risk groups,' the authors concluded. 'Designating GG1 on biopsy as noncancer without considering the prognostic values of adverse clinical features may lead to undertreatment and an increased risk of cancer-specific death in men with non-low-risk disease.' SOURCE: The study, led by Neal A. Patel, MD, Weill Cornell Medicine, New York City, was published online in JAMA Oncology. LIMITATIONS: Analysis lacked data on MRI and targeted biopsy use and did not account for prostate volume, which affects PSA levels. Histologic grading varied across pathologists due to nonstandardized assessments. Additionally, details on active surveillance intensity and watchful-waiting protocols were unavailable. DISCLOSURES: The study received support from the Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust and the Sandra and Edward Meyer Cancer Center of Weill Cornell Medicine. One author reported serving on the advisory board for Lantheus, Lynx Dx, Pacific Edge, and Pfizer/Astellas and receiving grants from the National Cancer Institute outside the submitted work. No other conflicts of interest were reported. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
3 hours ago
- Medscape
Urinary Sodium-Potassium Ratio May Signal Heart Health in RA
TOPLINE: In patients with rheumatoid arthritis (RA), higher urinary sodium-to-potassium ratio and sodium excretion were correlated with impaired coronary microvascular perfusion and might serve as an indicator. METHODOLOGY: Researchers conducted a cross-sectional study to investigate whether sodium and potassium intake and the ratio between urinary sodium and potassium excretion were associated with cardiovascular disease markers in patients with RA. They included 61 adults with RA (mean age, 62.4 years; 78.7% women; 65% reported a history of hypertension) from the outpatient department of a hospital in Greece. Assessments included markers of inflammation, estimated glomerular filtration rate (eGFR), disease activity using the 28-joint Disease Activity score, and other relevant parameters. Sodium and potassium excretion was calculated using 24-hour urine samples. Daily sodium intake was estimated assuming the urinary sodium excretion of 93%, and daily potassium intake was estimated assuming a gastrointestinal absorption of 77%. Coronary microvascular perfusion was evaluated using the subendocardial viability ratio (SEVR) measured with applanation tonometry; arterial stiffness was evaluated using pulse wave velocity and an augmentation index normalised to 75 beats/min. TAKEAWAY: The 24-hour urinary sodium and potassium excretion corresponded to a daily salt and potassium mean intake of 6.7 and 2.1 g, respectively. The mean urinary sodium-to-potassium ratio was 2.4, with only two patients showing an optimal ratio of ≤ 1. Urinary sodium excretion was significantly associated with high-density lipoprotein cholesterol levels (correlation coefficient [r], -0.309; P = .016) and uric acid levels (r, 0.301; P = .028). Urinary potassium excretion was positively associated with the eGFR (r, 0.371; P = .004), whereas it was negatively associated with disease activity (r, -0.387) and systemic inflammation (r, -0.269; P < .05 for both). Urinary sodium excretion (beta [β], -0.247; P = .034) and urinary sodium-to-potassium ratio (β, -0.247; P = .026) were independently and inversely correlated with SEVR. Neither urinary sodium nor potassium (or their ratio) was linked to markers of arterial stiffness. IN PRACTICE: "[The study] findings add new evidence to the growing body of evidence regarding the importance of dietary sodium and potassium intake in terms of cardiovascular health, in a well-defined population of patients with RA," the authors of the study wrote. SOURCE: This study was led by Panagiota Anyfanti, 3rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. It was published online on August 01, 2025, in Clinical Rheumatology. LIMITATIONS: The findings were relevant only for patients with RA in the absence of a control group, thereby limiting generalisability. The associations observed in this cross-sectional study may have been influenced by several confounding factors, such as comorbidities and medication use. Reliable data on heart failure were unavailable. DISCLOSURES: An open access funding was provided by HEAL-Link Greece. The authors declared having no competing interests. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
